Advertisement
UK markets close in 8 hours 26 minutes

  • FTSE 100

    8,078.86
    0.00 (0.00%)
     

  • FTSE 250

    19,601.98
    0.00 (0.00%)
     

  • AIM

    753.12
    0.00 (0.00%)
     

  • GBP/EUR

    1.1651
    -0.0006 (-0.05%)
     

  • GBP/USD

    1.2508
    -0.0003 (-0.03%)
     

  • Bitcoin GBP

    51,429.09
    +27.65 (+0.05%)
     

  • CMC Crypto 200

    1,390.80
    -5.73 (-0.41%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CRUDE OIL

    83.94
    +0.37 (+0.44%)
     

  • GOLD FUTURES

    2,354.10
    +11.60 (+0.50%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,682.41
    +397.87 (+2.30%)
     

  • DAX

    17,917.28
    -171.42 (-0.95%)
     

  • CAC 40

    8,016.65
    -75.21 (-0.93%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

Novartis’s Q2 2018 Estimates: Innovative Medicines Business

Mike Benson
Updated
Novartis’s Q2 2018 Estimates: Innovative Medicines Business

Novartis’s (NVS) Innovative Medicines segment includes cardio-metabolic, oncology, immunology, dermatology, respiratory, neuroscience, and established products. The chart below compares revenues for its Innovative Medicines business since the first quarter of 2017. Novartis’s (NVS) Innovative Medicines business is expected to report second-quarter growth in its operating revenues. This segment’s second-quarter growth is expected to be partially offset by lower sales of ophthalmology products and established medicines.

Continue reading